Jones Trading Lowers Opus Genetics (NASDAQ:IRD) Price Target to $8.00

Opus Genetics (NASDAQ:IRD) had its target price trimmed by Jones Trading from $9.00 to $8.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Opus Genetics in a research note on Tuesday.

Opus Genetics Stock Performance

Shares of NASDAQ IRD opened at $0.91 on Tuesday. The stock has a market cap of $29.16 million, a PE ratio of -0.83 and a beta of 0.28. Opus Genetics has a 1 year low of $0.81 and a 1 year high of $1.56. The company’s 50-day simple moving average is $1.07.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The company had revenue of $3.40 million during the quarter, compared to the consensus estimate of $11.10 million. On average, research analysts anticipate that Opus Genetics will post -1.22 earnings per share for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.